Hyaluronic Acid Supplements: Do They Work for Joints and Skin?

Hyaluronic Acid Supplements: What the Evidence Shows for Joints and Skin

Hyaluronic acid (HA) — also called hyaluronan — is one of the most abundant polysaccharides in the human body, and it is found in virtually every tissue, with the highest concentrations in synovial fluid, the vitreous of the eye, and the dermal extracellular matrix. It has been used medically for decades as an injectable agent for knee osteoarthritis and as a dermal filler. The question the evidence must answer is whether oral supplementation — taking HA by mouth — can meaningfully influence its concentrations in target tissues.

What Hyaluronic Acid Does in the Body

HA is a glycosaminoglycan — a long-chain polysaccharide composed of repeating disaccharide units (glucuronic acid and N-acetylglucosamine). Its defining physical property is extraordinary water-retention capacity: HA can bind and hold up to 1,000 times its weight in water, giving it a viscous, gel-like structure that is fundamental to its biological roles.

In synovial fluid (the lubricating fluid in joints), HA provides viscosity and elasticity — the "shock absorbing" quality that protects cartilage under compressive loads. Osteoarthritis is characterised by reduced HA concentration and molecular weight in synovial fluid, contributing to the loss of lubrication and increased cartilage wear.

In skin, HA is the primary structural component of the dermal matrix, binding water and maintaining turgor, plumpness, and elasticity. Skin HA content falls significantly with age: by the time a person reaches their 40s, dermal HA is estimated to be approximately 50% of young-adult levels; by 60–70, reductions are more profound. This is a major driver of skin thinning, loss of elasticity, and increased wrinkling.

Oral Absorption: The Critical Question

Scepticism about oral HA supplementation historically centred on whether it could survive gastrointestinal digestion (HA is a large polysaccharide) and whether absorbed fragments could reach and influence skin or joint tissue. The evidence has matured considerably on this question.

Radiotracer studies have demonstrated that orally administered HA is cleaved in the intestine into oligosaccharides and disaccharides, which are then absorbed and distributed to body tissues. A 2008 study by Balogh and colleagues tracked radiolabelled HA in rats and confirmed tissue accumulation in skin, liver, and other organs following oral administration. A 2015 human pharmacokinetic study by Oe and colleagues using 35S-labelled HA fragments confirmed accumulation in skin tissue in healthy adults.

These absorption studies address the fundamental mechanistic objection and confirm that oral HA does reach its target tissues — even if not as intact large-molecular-weight polymer.

Skin Evidence: The Human RCTs

The 2012 Kawada trial (Archives of Dermatological Research) examined 96 Japanese women randomly assigned to HA (120mg/day or 240mg/day) or placebo for 12 weeks. Participants in both HA groups showed significant improvements in skin moisture, wrinkle depth (measured by skin surface analysis), and subjective smoothness compared to placebo. The improvements were dose-dependent and statistically significant.

The 2022 Tashiro trial (Nutrients) was a double-blind RCT in 88 adults examining 120mg/day of HA vs placebo for 12 weeks. Using objective skin hydration measurements, the HA group showed significant improvements in skin elasticity and hydration at 8 and 12 weeks. The researchers also measured markers of HA metabolism in skin biopsies and found elevated hyaluronan synthase gene expression in the HA group, suggesting a systemic signal was stimulating endogenous HA production — a finding that partially explains why absorbed fragments could have effects disproportionate to their quantity.

A 2021 systematic review by Tashiro and colleagues summarised available RCT data and found consistent improvements in skin hydration and elasticity across multiple trials, with the strongest evidence for 120mg per day over at least 8 weeks.

Joint Pain Evidence

The evidence for oral HA in joint pain is more modest but directionally positive. The most cited trial is by Tashiro and colleagues (Nutrition Journal, 2012), a double-blind RCT in 60 patients with knee pain (not necessarily clinical osteoarthritis) randomised to 200mg/day HA or placebo for 12 months. The HA group showed significantly greater improvement in pain scores (VAS scale) and physical function measures (WOMAC subscales) compared to placebo.

A 2016 meta-analysis by Oe and colleagues identified four RCTs examining oral HA in knee osteoarthritis, finding a statistically significant overall effect on pain reduction (SMD -0.42, 95% CI -0.71 to -0.12). This is a small-to-moderate effect size — meaningful but not dramatic. Oral HA is not a replacement for physiotherapy, weight management, or intra-articular injection in established osteoarthritis, but it may provide modest additive benefit.

Molecular Weight Considerations

HA supplements vary in molecular weight, typically ranging from low-molecular-weight (5–50 kDa) to high-molecular-weight (>1,000 kDa). Low-molecular-weight HA is more readily absorbed from the gut. Some evidence suggests that very low-molecular-weight HA fragments have signalling properties (activating hyaluronan receptors and stimulating endogenous HA synthesis) distinct from their physical viscosity. Products specifying molecular weight and providing low-to-intermediate MW HA may offer better bioavailability. However, most clinical trials do not specify molecular weight in ways that allow clear comparative conclusions.

Dosing and Safety

The dose range used across clinical trials is 120–200mg per day, with most skin studies using 120mg and most joint studies using 120–200mg. The duration of consistent use needed to see effects appears to be at least 8 weeks, with 12 weeks being the typical trial endpoint.

Oral HA is very well tolerated. No significant adverse effects have been reported in human trials at these doses. It is suitable for long-term use.

Bottom Line

Oral hyaluronic acid is well-supported by both mechanistic and clinical data. Tracer studies confirm tissue distribution following oral dosing; multiple RCTs demonstrate significant improvements in skin hydration and elasticity at 120mg/day over 8–12 weeks; and meta-analytic data supports modest but significant joint pain reduction in knee osteoarthritis. At 120–200mg daily, HA is a well-evidenced supplement for skin quality and joint comfort — particularly from mid-life onward when endogenous HA production declines.